Balchem Expands Credit Facility by $100 Million with Extended Maturity to 2031 and Improved Borrowing Terms

Significant Boost to Liquidity with Increased Borrowing Capacity

Balchem Corporation’s credit agreement amendment substantially enhances its liquidity profile by increasing the revolving credit capacity by $100 million—from $550 million to $650 million. This expansion, formalized on July 24, 2026, with JPMorgan Chase Bank, N.A. and JPMorgan SE as administrative agents, equips the Maryland-based specialty chemicals firm with greater financial agility to manage working capital, fund expansion projects, and meet operational needs.

The increased borrowing capacity amid a competitive lending market underscores lenders’ confidence in Balchem’s creditworthiness and operational strength. Operating in the specialty chemicals sector, which demands significant working capital for inventory and client management, the additional funds provide management with flexibility to capitalize on market opportunities, handle seasonal business variations, and pursue strategic acquisitions or capital expenditures without immediate refinancing or equity issuance.

Extended Facility Maturity Adds Long-Term Financial Stability

The credit facility’s maturity has been extended from July 27, 2027, to July 24, 2031, offering Balchem a four-year longer financial runway. This extension reduces near-term refinancing risks and grants management greater certainty about credit availability over the long term, a critical advantage amid economic uncertainties. It allows Balchem to concentrate on organic growth and operational execution instead of refinancing concerns.

This maturity extension also reflects lenders’ commitment to Balchem’s long-term viability, signaling investor confidence in the company’s sustainable business model and financial health. Typically, such extensions require lenders to trust the borrower’s ability to maintain debt service and financial metrics throughout the facility’s duration. The July 2031 maturity aligns with Balchem’s strategic planning and minimizes refinancing uncertainties during this period.

Improved Borrowing Costs Through Pricing Adjustments

The amended credit agreement delivers meaningful reductions in borrowing costs by eliminating a 10 basis point SOFR adjustment and lowering margins by 12.5 basis points at Tier 3 and Tier 4 leverage levels. The updated pricing grid features four tiers based on the Consolidated Net Leverage Ratio under the amended terms.

Under the new structure, borrowing rates vary by leverage: Tier 1 (below 1.00:1.00) carries a 1.00% rate with zero letter of credit fees; Tier 2 (1.00:1.00 to 2.00:1.00) has a 1.125% rate and 0.125% letter of credit fees; Tier 3 (2.00:1.00 to 3.00:1.00) features a 1.250% rate and 0.250% fees; and Tier 4 (above 3.00:1.00) applies 1.500% rates with 0.500% fees. These reductions lower Balchem’s cost of capital and improve net interest expense, positively impacting earnings quality.

Expanded International Borrowing Flexibility via Foreign Subsidiary

The amendment authorizes Balchem B.V., the company’s foreign subsidiary, to borrow directly under the credit facility. This provision enhances Balchem’s ability to manage cash flow and working capital internationally, optimizing its capital structure and reducing reliance on intercompany loans that may be less tax-efficient or operationally effective.

Enabling direct borrowing by Balchem B.V. supports funding for European and other international operations more efficiently, allowing rapid responses to foreign market working capital needs without delays from intercompany financing approvals. This enhancement highlights the lending syndicate’s support for Balchem’s global growth and operational management.

Security and Guarantor Agreements Maintained

Balchem and certain domestic subsidiaries executed an Omnibus Reaffirmation and Amendment Agreement reaffirming the terms of the Amended and Restated Security and Pledge Agreement dated July 27, 2022. This ensures that existing security interests and guarantor obligations remain effective under the amended credit facility.

Domestic subsidiaries continue as guarantors, providing customary credit support and collateral coverage to lenders. This structure helps secure favorable pricing and terms by maintaining priority claims on company assets in the event of default. The reaffirmation indicates no major changes to collateral or guarantor arrangements were needed to accommodate the increased commitment and extended maturity.

JPMorgan Chase Leads Syndicate as Administrative Agent

JPMorgan Chase Bank, N.A. and JPMorgan SE serve as joint administrative agents for the credit facility. Their dual role as lenders and administrators reflects a strong relationship with Balchem and confidence in the company’s credit profile. JPMorgan Chase’s ongoing participation and expanded commitment validate Balchem’s financial stability and growth prospects.

As administrative agents, JPMorgan Chase coordinates the lending syndicate, manages documentation, processes payments, and monitors compliance with covenants. Their involvement indicates in-depth knowledge of Balchem’s operations and financial health. The decision to increase the facility and extend maturity likely stems from positive assessments of Balchem’s performance and outlook by the agents and syndicate.

Investor Implications and Enhanced Financial Flexibility

The expanded credit facility and extended maturity considerably improve Balchem’s financial flexibility and reduce refinancing risk. Investors may interpret the amendment as a strong endorsement of the company’s fundamentals and debt servicing ability. The additional $100 million borrowing capacity equips management with resources to pursue strategic initiatives, capital investments, or balance sheet strengthening as market conditions evolve.

Lower borrowing costs from margin reductions and SOFR adjustment elimination will decrease net interest expenses and enhance reported earnings. The scale of savings depends on borrowing levels and leverage tiers but is expected to positively impact profitability. Over the four-year extended term, these improvements could significantly benefit shareholder returns and financial metrics.

Disclosures and Limitations for Investors

Balchem noted that representations, warranties, and covenants in the loan documents are intended solely for the contracting parties and are subject to materiality standards that may differ from those applicable to public investors. Investors should not rely on these as precise reflections of Balchem’s actual financial or operational status.

The company also cautioned that information related to these representations may change post-execution and might not be fully disclosed publicly. This standard disclaimer protects Balchem and lenders from being bound by outdated information and highlights the importance of reviewing ongoing regulatory filings, quarterly earnings, and public disclosures for current financial and operational data. The full amended credit agreement and related documents are available as exhibits to the current report, detailing all terms, conditions, and covenants governing the facility.